Researchers say CSF biomarker test correlates with the severity of cognitive decline, independent of other factors, including brain amyloid deposition.

Guillain-Barré Syndrome (GBS) poses a diagnostic challenge due to its misleading symptoms, the lack of a definitive test, and ...